Product Description
13-valent pneumococcal vaccine
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Otitis Media|Pneumococcal Infections|Meningitis, Pneumococcal|Meningitis, Bacterial
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00617760 |
Prevenar® | P3 |
Completed |
Meningitis, Pneumococcal|Pneumococcal Infections|Meningitis, Bacterial |
2009-08-01 |
2019-03-18 |
||
NCT00378417 |
KTL69-0 | P3 |
Completed |
Otitis Media|Pneumococcal Infections |
None |
2022-05-04 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|